Table of Content


1 EXECUTIVE SUMMARY ............................................................................................................... 21

2 MARKET INTRODUCTION ............................................................................................................ 23
2.1 DEFINITION .................................................................................................................................................................. 23
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 23
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 23
2.4 MARKET STRUCTURE .............................................................................................................................................. 23

3 RESEARCH METHODOLOGY ...................................................................................................... 24
3.1 OVERVIEW .................................................................................................................................................................... 24
3.2 DATA FLOW .................................................................................................................................................................. 26
3.2.1 DATA MINING PROCESS ................................................................................................................................. 26
3.3 PURCHASED DATABASE: ......................................................................................................................................... 27
3.4 SECONDARY SOURCES: ............................................................................................................................................ 28
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 29
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 30
3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 31
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 32
3.6.1 REVENUE ANALYSIS APPROACH ..................................................................................................................... 32
3.7 DATA FORECASTING................................................................................................................................................. 33
3.7.1 DATA FORECASTING TYPE .............................................................................................................................. 33
3.8 DATA MODELING ........................................................................................................................................................ 34
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................................ 34
3.8.2 DATA MODELING: ........................................................................................................................................... 35
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 37

4 MARKET DYNAMICS .................................................................................................................... 39
4.1 INTRODUCTION ........................................................................................................................................................... 39
4.2 DRIVERS ......................................................................................................................................................................... 40
4.2.1 RISING AWARENESS AND IMPROVED DIAGNOSIS ............................................................................................ 40
4.2.2 INNOVATIVE PRODUCT FORMULATIONS ......................................................................................................... 40
4.2.3 RISE IN DISPOSABLE INCOME AND SPENDING ON SKINCARE ........................................................................... 41
4.3 RESTRAINTS ................................................................................................................................................................ 42
4.3.1 SIDE EFFECTS ASSOCIATED WITH THE XEROSIS TREATMENT DRUGS .............................................................. 42
4.4 OPPORTUNITY ............................................................................................................................................................. 43
4.4.1 GROWING GERIATRIC POPULATION ................................................................................................................ 43
4.4.2 INCREASE IN SELF-CARE PRACTICES FOR XEROSIS ......................................................................................... 44
4.4.3 ONGOING CLINICAL TRIALS AND UNIVERSITIES STUDIES ................................................................................. 44
MARKET FACTOR ANALYSIS ............................................................................................................ 45
4.5 PORTER’S FIVE FORCES MODEL ........................................................................................................................... 45
4.5.1 THREAT OF NEW ENTRANTS ........................................................................................................................... 45
4.5.2 BARGAINING POWER OF SUPPLIERS ............................................................................................................... 46
4.5.3 THREAT OF SUBSTITUTES .............................................................................................................................. 46
4.5.4 BARGAINING POWER OF BUYERS .................................................................................................................... 46
4.5.5 INTENSITY OF RIVALRY .................................................................................................................................. 46
4.6 IMPACT OF COVID-19 ON GLOBAL XEROSIS TREATMENT MARKET ...................................................... 47
4.7 EPIDEMIOLOGY ANALYSIS ..................................................................................................................................... 47
4.8 MARKET TRENDS ...................................................................................................................................................... 48

5 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE ................................................................. 51
5.1 OVERVIEW .................................................................................................................................................................... 51
5.2 MEDICATION ................................................................................................................................................................ 53
5.2.1 ANTIHISTAMINES ........................................................................................................................................... 54
5.2.2 CORTICOSTEROIDS ......................................................................................................................................... 55
5.2.3 CALCINEURIN INHIBITORS .............................................................................................................................. 55
5.2.4 ANTI-INFLAMMATORY .................................................................................................................................... 56
5.2.5 IMMUNOMODULATORS ................................................................................................................................... 56
5.2.6 OTHERS ......................................................................................................................................................... 57
5.3 PERSONAL CARE PRODUCTS ................................................................................................................................. 57

6 GLOBAL XEROSIS TREATMENT MARKET, BY FORM ............................................................... 58
6.1 OVERVIEW .................................................................................................................................................................... 58
6.2 TABLETS........................................................................................................................................................................ 61
6.3 LOTION ........................................................................................................................................................................... 61
6.4 CREAM ........................................................................................................................................................................... 62
6.5 OINTMENT .................................................................................................................................................................... 62
6.6 SHOWER FOAMS ........................................................................................................................................................ 63
6.7 OTHERS .......................................................................................................................................................................... 63

7 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP .................................................... 64
7.1 OVERVIEW .................................................................................................................................................................... 64
7.2 PAEDIATRICS ............................................................................................................................................................... 66
7.3 ADULTS .......................................................................................................................................................................... 67
7.4 ELDERLY ........................................................................................................................................................................ 67

8 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER ........................................................... 68
8.1 OVERVIEW .................................................................................................................................................................... 68
8.2 MALE .............................................................................................................................................................................. 70
8.3 FEMALE ......................................................................................................................................................................... 71

9 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL ............................... 72
9.1 OVERVIEW .................................................................................................................................................................... 72
9.2 ONLINE ........................................................................................................................................................................... 74
9.3 OFFLINE ......................................................................................................................................................................... 75

10 GLOBAL XEROSIS TREATMENT MARKET, BY REGION ............................................................ 76
10.1 OVERVIEW .................................................................................................................................................................... 76
10.2 NORTH AMERICA ....................................................................................................................................................... 77
10.2.1 US.................................................................................................................................................................. 81
10.2.2 CANADA ........................................................................................................................................................ 83
10.3 EUROPE .......................................................................................................................................................................... 85
10.3.1 GERMANY ...................................................................................................................................................... 89
10.3.2 FRANCE ......................................................................................................................................................... 91
10.3.3 UK ................................................................................................................................................................. 93
10.3.4 SPAIN ............................................................................................................................................................ 95
10.3.5 ITALY ............................................................................................................................................................. 97
10.3.6 RUSSIA .......................................................................................................................................................... 99
10.3.7 REST OF EUROPE ............................................................................................................................................ 101
10.4 ASIA PACIFIC ............................................................................................................................................................... 103
10.4.1 CHINA ............................................................................................................................................................ 107
10.4.2 INDIA ............................................................................................................................................................. 109
10.4.3 JAPAN ........................................................................................................................................................... 111
10.4.4 SOUTH KOREA ................................................................................................................................................ 113
10.4.5 MALAYSIA ..................................................................................................................................................... 116
10.4.6 THAILAND ...................................................................................................................................................... 118
10.4.7 INDONESIA ..................................................................................................................................................... 120
10.4.8 REST OF ASIA PACIFIC.................................................................................................................................... 122
10.5 SOUTH AMERICA ....................................................................................................................................................... 124
10.5.1 BRAZIL ........................................................................................................................................................... 128
10.5.2 MEXICO ......................................................................................................................................................... 130
10.5.3 ARGENTINA ................................................................................................................................................... 132
10.5.4 REST OF SOUTH AMERICA .............................................................................................................................. 134
10.6 MIDDLE EAST AND AFRICA .................................................................................................................................... 136
10.6.1 GCC COUNTRIES............................................................................................................................................. 140
10.6.2 SOUTH AFRICA ............................................................................................................................................... 142
10.6.3 REST OF MEA ................................................................................................................................................. 144

11 COMPETITIVE LANDSCAPE ........................................................................................................ 148
11.1 INTRODUCTION ........................................................................................................................................................... 148
11.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 148
11.3 COMPETITOR DASHBOARD..................................................................................................................................... 149
11.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 150
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL .............................................................................. 150
11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 151
11.1.1 PRODUCT LAUNCH ......................................................................................................................................... 151

12 COMPANY PROFILES .................................................................................................................. 152
12.1 AMGEN INC................................................................................................................................................................... 152
12.1.1 COMPANY OVERVIEW ..................................................................................................................................... 152
12.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 153
12.1.3 PRODUCTS OFFERED ...................................................................................................................................... 154
12.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 154
12.1.5 SWOT ANALYSIS ............................................................................................................................................ 154
12.1.6 KEY STRATEGIES ............................................................................................................................................ 155
12.2 PROCTER & GAMBLE ................................................................................................................................................. 156
12.2.1 COMPANY OVERVIEW ..................................................................................................................................... 156
12.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 157
12.2.3 PRODUCTS OFFERED ...................................................................................................................................... 158
12.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 158
12.2.5 SWOT ANALYSIS ............................................................................................................................................ 159
12.2.6 KEY STRATEGIES ............................................................................................................................................ 159
12.3 UNILEVER ..................................................................................................................................................................... 160
12.3.1 COMPANY OVERVIEW ..................................................................................................................................... 160
12.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 161
12.3.3 PRODUCTS OFFERED ...................................................................................................................................... 162
12.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 162
12.3.5 KEY STRATEGIES ............................................................................................................................................ 163
12.4 PFIZER INC. ................................................................................................................................................................... 164
12.4.1 COMPANY OVERVIEW ..................................................................................................................................... 164
12.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 165
12.4.3 PRODUCTS OFFERED ...................................................................................................................................... 166
12.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 166
12.4.5 SWOT ANALYSIS ............................................................................................................................................ 166
12.4.6 KEY STRATEGIES ............................................................................................................................................ 167
12.5 CIPLA .............................................................................................................................................................................. 168
12.5.1 COMPANY OVERVIEW ..................................................................................................................................... 168
12.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 169
12.5.3 PRODUCTS OFFERED ...................................................................................................................................... 169
12.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 169
12.5.5 KEY STRATEGIES ............................................................................................................................................ 170
12.6 BAYER AG ..................................................................................................................................................................... 170
12.6.1 COMPANY OVERVIEW ..................................................................................................................................... 170
12.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 172
12.6.3 PRODUCTS OFFERED ...................................................................................................................................... 172
12.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 173
12.6.5 SWOT ANALYSIS ............................................................................................................................................ 173
12.6.6 KEY STRATEGY ............................................................................................................................................... 173
12.7 JOHNSON & JOHNSON INC. ..................................................................................................................................... 175
12.7.1 COMPANY OVERVIEW ..................................................................................................................................... 175
12.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 176
12.7.3 PRODUCTS OFFERED ...................................................................................................................................... 177
12.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 177
12.7.5 SWOT ANALYSIS ............................................................................................................................................ 178
12.7.6 KEY STRATEGIES ............................................................................................................................................ 178
12.8 GALDERMA ................................................................................................................................................................... 179
12.8.1 COMPANY OVERVIEW ..................................................................................................................................... 179
12.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 180
12.8.3 PRODUCT OFFERED ........................................................................................................................................ 180
12.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 181
12.8.5 KEY STRATEGIES ............................................................................................................................................ 181
12.9 DR. REDDY’S LABORATORIES LTD. ....................................................................................................................... 182
12.9.1 COMPANY OVERVIEW ................................................................................................................................... 182
12.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 183
12.9.3 PRODUCT OFFERED ........................................................................................................................................ 183
12.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 184
12.9.5 KEY STRATEGIES ............................................................................................................................................ 184
12.10 THORNTON & ROSS LTD. .......................................................................................................................................... 185
12.10.1 COMPANY OVERVIEW ..................................................................................................................................... 185
12.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 185
12.10.3 PRODUCT OFFERED ........................................................................................................................................ 185
12.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 186
12.10.5 KEY STRATEGIES ............................................................................................................................................ 186

13 DATA CITATIONS ......................................................................................................................... 187



List of Figures

LIST OF FIGURES
FIGURE 1 GLOBAL XEROSIS MARKET: STRUCTURE 23
FIGURE 2 GLOBAL XEROSIS TREATMENT: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 39
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 42
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 43
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL XEROSIS TREATMENT MARKET 45
FIGURE 6 GLOBAL XEROSIS TREATMENT MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 52
FIGURE 7 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2023 & 2032 (USD MILLION) 52
FIGURE 8 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY TYPE, 2023 53
FIGURE 9 GLOBAL XEROSIS TREATMENT MARKET, FORM SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 59
FIGURE 10 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2023 & 2032 (USD MILLION) 59
FIGURE 11 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY FORM, 2023 60
FIGURE 12 GLOBAL XEROSIS TREATMENT MARKET, AGE GROUP SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 65
FIGURE 13 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION) 65
FIGURE 14 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY AGE GROUP, 2023 66
FIGURE 15 GLOBAL XEROSIS TREATMENT MARKET, GENDER SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 69
FIGURE 16 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2023 & 2032 (USD MILLION) 69
FIGURE 17 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY GENDER, 2023 70
FIGURE 18 GLOBAL XEROSIS TREATMENT MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 73
FIGURE 19 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION) 73
FIGURE 20 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023 74
FIGURE 21 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2023 & 2032 (USD MILLION) 76
FIGURE 22 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY REGION, 2023 77
FIGURE 23 NORTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 78
FIGURE 24 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 78
FIGURE 25 NORTH AMERICA XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023 79
FIGURE 26 EUROPE MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 86
FIGURE 27 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 86
FIGURE 28 EUROPE XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023 87
FIGURE 29 ASIA PACIFIC MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 104
FIGURE 30 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 104
FIGURE 31 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%) 105
FIGURE 32 SOUTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 124
FIGURE 33 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 125
FIGURE 34 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%) 125
FIGURE 35 MIDDLE EAST AND AFRICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION) 136
FIGURE 36 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 137
FIGURE 37 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%) 137
FIGURE 38 GLOBAL XEROSIS TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 148
FIGURE 39 COMPETITOR DASHBOARD: GLOBAL XEROSIS TREATMENT MARKET 149
FIGURE 40 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 153
FIGURE 41 AMGEN INC.: SWOT ANALYSIS 154
FIGURE 42 PROCTER & GAMBLE: FINANCIAL OVERVIEW SNAPSHOT 157
FIGURE 43 PROCTER & GAMBLE: SWOT ANALYSIS 159
FIGURE 44 UNILEVER: FINANCIAL OVERVIEW SNAPSHOT 161
FIGURE 45 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 165
FIGURE 46 PFIZER INC.: SWOT ANALYSIS 166
FIGURE 47 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 169
FIGURE 48 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 172
FIGURE 49 BAYER AG: SWOT ANALYSIS 173
FIGURE 50 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT 176
FIGURE 51 JOHNSON & JOHNSON INC.: SWOT ANALYSIS 178
FIGURE 52 GALDERMA: FINANCIAL OVERVIEW SNAPSHOT 180
FIGURE 53 DR. REDDY’S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 183

List of Tables

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 35
TABLE 2 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 53
TABLE 3 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY REGION, 2019–2032 (USD MILLION) 53
TABLE 4 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 54
TABLE 5 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019–2032 (USD MILLION) 54
TABLE 6 GLOBAL XEROSIS TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2019–2032 (USD MILLION) 55
TABLE 7 GLOBAL XEROSIS TREATMENT MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2019–2032 (USD MILLION) 55
TABLE 8 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 9 GLOBAL XEROSIS TREATMENT MARKET, FOR IMMUNOMODULATORS, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 10 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 57
TABLE 11 GLOBAL XEROSIS TREATMENT MARKET, FOR PERSONAL CARE PRODUCTS, BY REGION, 2019–2032 (USD MILLION) 57
TABLE 12 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 60
TABLE 13 GLOBAL XEROSIS TREATMENT MARKET, FOR TABLETS, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 14 GLOBAL XEROSIS TREATMENT MARKET, FOR LOTION, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 15 GLOBAL XEROSIS TREATMENT MARKET, FOR CREAM, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 16 GLOBAL XEROSIS TREATMENT MARKET, FOR OINTMENT, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 17 GLOBAL XEROSIS TREATMENT MARKET, FOR SHOWER FOAMS, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 18 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 19 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 66
TABLE 20 GLOBAL XEROSIS TREATMENT MARKET, FOR PAEDIATRICS, BY REGION, 2019–2032 (USD MILLION) 66
TABLE 21 GLOBAL XEROSIS TREATMENT MARKET, FOR ADULTS, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 22 GLOBAL XEROSIS TREATMENT MARKET, FOR ELDERLY, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 23 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 69
TABLE 24 GLOBAL XEROSIS TREATMENT MARKET, FOR MALE, BY REGION, 2019–2032 (USD MILLION) 70
TABLE 25 GLOBAL XEROSIS TREATMENT MARKET, FOR FEMALE, BY REGION, 2019–2032 (USD MILLION) 71
TABLE 26 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 74
TABLE 27 GLOBAL XEROSIS TREATMENT MARKET, FOR ONLINE, BY REGION, 2019–2032 (USD MILLION) 74
TABLE 28 GLOBAL XEROSIS TREATMENT MARKET, FOR OFFLINE, BY REGION, 2019–2032 (USD MILLION) 75
TABLE 29 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2019–2032 (USD MILLION) 76
TABLE 30 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 79
TABLE 31 NORTH AMERICA XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 79
TABLE 32 NORTH AMERICA XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 80
TABLE 33 NORTH AMERICA XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 80
TABLE 34 NORTH AMERICA XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 80
TABLE 35 NORTH AMERICA XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 81
TABLE 36 NORTH AMERICA XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 81
TABLE 37 US: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 81
TABLE 38 US: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 82
TABLE 39 US: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 82
TABLE 40 US: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 82
TABLE 41 US: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 83
TABLE 42 US: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 83
TABLE 43 CANADA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 44 CANADA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 45 CANADA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 84
TABLE 46 CANADA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 84
TABLE 47 CANADA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 85
TABLE 48 CANADA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 85
TABLE 49 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 87
TABLE 50 EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 87
TABLE 51 EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 88
TABLE 52 EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 88
TABLE 53 EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 88
TABLE 54 EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 89
TABLE 55 EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 89
TABLE 56 GERMANY: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 57 GERMANY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 90
TABLE 58 GERMANY: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 90
TABLE 59 GERMANY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 90
TABLE 60 GERMANY: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 91
TABLE 61 GERMANY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 91
TABLE 62 FRANCE: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 91
TABLE 63 FRANCE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 64 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 92
TABLE 65 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 92
TABLE 66 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 93
TABLE 67 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 93
TABLE 68 UK: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 93
TABLE 69 UK: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 94
TABLE 70 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 94
TABLE 71 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 94
TABLE 72 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 95
TABLE 73 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 95
TABLE 74 SPAIN: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 75 SPAIN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 96
TABLE 76 SPAIN: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 96
TABLE 77 SPAIN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 96
TABLE 78 SPAIN: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 97
TABLE 79 SPAIN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 97
TABLE 80 ITALY: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 97
TABLE 81 ITALY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 82 ITALY: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 98
TABLE 83 ITALY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 98
TABLE 84 ITALY: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 99
TABLE 85 ITALY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 99
TABLE 86 RUSSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 99
TABLE 87 RUSSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 100
TABLE 88 RUSSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 100
TABLE 89 RUSSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 100
TABLE 90 RUSSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 101
TABLE 91 RUSSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 101
TABLE 92 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 93 REST OF EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 102
TABLE 94 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 102
TABLE 95 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 102
TABLE 96 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 103
TABLE 97 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 103
TABLE 98 ASIA PACIFIC XEROSIS TREATMENT MARKET, BY REGION, 2019–2032 (USD MILLION) 105
TABLE 99 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 105
TABLE 100 ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 106
TABLE 101 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 106
TABLE 102 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 106
TABLE 103 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 107
TABLE 104 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 107
TABLE 105 CHINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 107
TABLE 106 CHINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 108
TABLE 107 CHINA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 108
TABLE 108 CHINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 108
TABLE 109 CHINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 109
TABLE 110 CHINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 109
TABLE 111 INDIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 109
TABLE 112 INDIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 110
TABLE 113 INDIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 110
TABLE 114 INDIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 110
TABLE 115 INDIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 111
TABLE 116 INDIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 111
TABLE 117 JAPAN: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 111
TABLE 118 JAPAN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 111
TABLE 119 JAPAN: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 112
TABLE 120 JAPAN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 112
TABLE 121 JAPAN: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 113
TABLE 122 JAPAN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 113
TABLE 123 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 113
TABLE 124 SOUTH KOREA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 114
TABLE 125 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 114
TABLE 126 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 115
TABLE 127 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 115
TABLE 128 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 115
TABLE 129 MALAYSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 116
TABLE 130 MALAYSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 116
TABLE 131 MALAYSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 116
TABLE 132 MALAYSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 117
TABLE 133 MALAYSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 117
TABLE 134 MALAYSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 117
TABLE 135 THAILAND: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 118
TABLE 136 THAILAND: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 118
TABLE 137 THAILAND: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 118
TABLE 138 THAILAND: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 119
TABLE 139 THAILAND: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 119
TABLE 140 THAILAND: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 119
TABLE 141 INDONESIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 120
TABLE 142 INDONESIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 120
TABLE 143 INDONESIA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 120
TABLE 144 INDONESIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 121
TABLE 145 INDONESIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 121
TABLE 146 INDONESIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 121
TABLE 147 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 122
TABLE 148 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 122
TABLE 149 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 122
TABLE 150 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 123
TABLE 151 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 123
TABLE 152 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 123
TABLE 153 SOUTH AMERICA XEROSIS TREATMENT MARKET, BY REGION, 2019–2032 (USD MILLION) 125
TABLE 154 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 126
TABLE 155 SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 126
TABLE 156 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 126
TABLE 157 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 127
TABLE 158 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 127
TABLE 159 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 127
TABLE 160 BRAZIL: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 128
TABLE 161 BRAZIL: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 128
TABLE 162 BRAZIL: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 128
TABLE 163 BRAZIL: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 129
TABLE 164 BRAZIL: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 129
TABLE 165 BRAZIL: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 129
TABLE 166 MEXICO: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 130
TABLE 167 MEXICO: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 130
TABLE 168 MEXICO: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 130
TABLE 169 MEXICO: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 131
TABLE 170 MEXICO: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 131
TABLE 171 MEXICO: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 131
TABLE 172 ARGENTINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 132
TABLE 173 ARGENTINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 132
TABLE 174 ARGENTINA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 132
TABLE 175 ARGENTINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 133
TABLE 176 ARGENTINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 133
TABLE 177 ARGENTINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 133
TABLE 178 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 134
TABLE 179 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 134
TABLE 180 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 134
TABLE 181 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 135
TABLE 182 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 135
TABLE 183 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 135
TABLE 184 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 137
TABLE 185 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 138
TABLE 186 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 138
TABLE 187 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 138
TABLE 188 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 139
TABLE 189 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 139
TABLE 190 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 139
TABLE 191 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 140
TABLE 192 GCC COUNTRIES: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 140
TABLE 193 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 141
TABLE 194 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 141
TABLE 195 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 141
TABLE 196 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 142
TABLE 197 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 142
TABLE 198 SOUTH AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 142
TABLE 199 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 143
TABLE 200 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 143
TABLE 201 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 143
TABLE 202 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 144
TABLE 203 REST OF MEA: XEROSIS TREATMENT MARKET, BY TYPE, 2019–2032 (USD MILLION) 144
TABLE 204 REST OF MEA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 144
TABLE 205 REST OF MEA: XEROSIS TREATMENT MARKET, BY FORM, 2019–2032 (USD MILLION) 145
TABLE 206 REST OF MEA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 145
TABLE 207 REST OF MEA: XEROSIS TREATMENT MARKET, BY GENDER, 2019–2032 (USD MILLION) 145
TABLE 208 REST OF MEA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 146
TABLE 209 PUBLIC PLAYERS STOCK SUMMARY 150
TABLE 210 PRODUCT LAUNCH 151
TABLE 211 AMGEN INC.: PRODUCTS OFFERED 154
TABLE 212 AMGEN INC.: KEY DEVELOPMENTS 154
TABLE 213 PROCTER & GAMBLE: PRODUCTS OFFERED 158
TABLE 214 PROCTER & GAMBLE: KEY DEVELOPMENTS 158
TABLE 215 UNILEVER: PRODUCTS OFFERED 162
TABLE 216 PFIZER INC.: PRODUCTS OFFERED 166
TABLE 217 CIPLA: PRODUCTS OFFERED 169
TABLE 218 BAYER AG: PRODUCTS OFFERED 172
TABLE 219 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED 177
TABLE 220 GALDERMA: PRODUCTS OFFERED 180
TABLE 221 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED 183
TABLE 222 THORNTON & ROSS LTD.: PRODUCTS OFFERED 185